A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)

PHASE2CompletedINTERVENTIONAL
Enrollment

272

Participants

Timeline

Start Date

December 18, 2017

Primary Completion Date

December 4, 2020

Study Completion Date

September 21, 2021

Conditions
Alzheimer Disease
Interventions
DRUG

Donanemab

Administered IV

DRUG

Placebo

Administered IV

DRUG

LY3202626

Administered orally

Trial Locations (61)

19090

Abington Neurological Associates, Willow Grove

22031

Cognition Health, Fairfax

23294

National Clinical Research - Richmond, Richmond

27103

Piedmont Medical Research, Winston-Salem

27405

Guilford Neurologic Associates, Greensboro

27607

Raleigh Neurology Associates, Raleigh

28211

Behavioral Health Center Research, Charlotte

32127

Progressive Medical Research, Port Orange

32162

Compass Research, The Villages

32216

Jacksonville Center for Clinical Research, Jacksonville

32592

Merritt Island Medical Research LLC, Merritt Island

32806

Compass Research, Orlando

33021

Infinity Clinical Research, LLC, Hollywood

33064

Quantum Laboratories, Pompano Beach

33126

Pharmax Research Clinic, Miami

33137

Miami Jewish Health Systems, Miami

33410

Palm Beach Neurological Group, Palm Beach Gardens

33445

Brain Matters Research, Delray Beach

33462

JEM Research Institute, Atlantis

33609

Axiom Research, Tampa

33613

Stedman Clinical Trials, Tampa

34205

Bradenton Research Center, Bradenton

34239

Intercoastal Medical Group, Sarasota

34652

Suncoast Clinical Research, New Port Richey

43210

Ohio State University Medical Center, Columbus

44122

Insight Clinical Trials, Beachwood

45459

Neurology Diagnostics, Inc., Dayton

46202

Indiana University School of Medicine, Indianapolis

46256

Josephson Wallack Munshower Neurology, Indianapolis

60007

Alexian Brothers Medical Center, Elk Grove Village

60640

Great Lakes Clinical Trials, Chicago

63108

Washington University, St Louis

66160

University of Kansas Hospital, Fairway

66606

Cotton O'Neil Clinic, Topeka

75214

Texas Neurology, PA, Dallas

77030

Houston Methodist, Houston

85006

Banner Alzheimer's Institute, Phoenix

85351

Banner Sun Health Research Institute, Sun City

89113

Las Vegas Medical Research, Las Vegas

92103

Pacific Research Network Inc, San Diego

92123

Sharp Mesa Vista Hospital, San Diego

92614

Irvine Clinical Research Center, Irvine

92660

Pharmacology Research Institute, Newport Beach

92697

Institute for Memory Impairment & Neurological Disorders, Irvine

92705

Syrentis Clinical Research, Santa Ana

92835

Neurology Center of North Orange County, Fullerton

06810

Associated Neurologists, PC - Danbury, Danbury

06905

KI Health Partners, LLC d/b/a NE Inst. for Clin. Res., Stamford

02478

McLean Hospital, Belmont

01844

ActivMed Practices & Research, Inc, Methuen

02459

Boston Center for Memory, Newton

02360-4843

Donald S Marks, Plymouth

08755

Advanced Memory Research Institute of New Jersey, Toms River

02903

Rhode Island Hospital, Providence

02906

Butler Hospital, Providence

05201

The Memory Clinic, Bennington

K1N 5C8

Bruyere Research Institute, Ottawa

K9H2P4

Kawartha Regional Memory Clinic, Peterborough

M3B2S7

Toronto Memory Program, Toronto

J8T 8J1

Clinique de la Memoire de l'Outaouais, Gatineau

J1L 0H8

DIEX Recherche Sherbrooke, Inc, Sherbrooke

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT03367403 - A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ) | Biotech Hunter | Biotech Hunter